Key facts
- Bilix’s last known valuation is $28.1M (Dec 2025).
- It has raised $10.0M; the latest was Later Stage VC ($19.5M) in Dec 2025.
- Notable investors include iM Investment Partners, BiiG WAVE, Magna Investment (Seoul), Alpen Route Asset Management, DS Capital — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Bilix
- ·The full record, as it builds
Funding rounds
No funding rounds for Bilix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bilix
Developer of PEGylated bilirubin nanoparticles designed to treat ischemia-reperfusion injury by reducing inflammation and oxidative stress. The company offers a nanoparticle-based therapy with demonstrated safety in early trials and a targeted application for cardiac surgery-associated acute kidney injury, enabling pharmaceutical companies, clinicians, and healthcare providers to address organ damage caused by interrupted and restored blood flow, improve surgical outcomes, and reduce the long-term burden of acute kidney injury.
- Sector
- Healthcare
- HQ
- Yongin, South Korea
- Founded
- 2018
- Employees
- 12
- Website
- bilix.com/
- Ownership
- Privately Held (backing)
Bilix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bilix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bilix in its N-PORT filings yet. We sweep new filings monthly.